ArticleBMJ open diabetes research & care2026
Integrated multicompartment urinary long non-coding RNAs profiling (cellular, cell-free, and extracellular vesicle) for better differential diagnosis of biopsy-proven diabetic and non-diabetic kidney disease beyond conventional markers.
Article in BMJ open diabetes research & care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRenal involvement in type 2 diabetes (T2DM) can be due to diabetes (diabetic kidney disease, DKD) or other causes (non-DKD, NDKD) or both (mixed kidney disease). Available clinical and laboratory parameters have limitations in predicting a diagnosis (gold standard renal biopsy). Long non-coding RNAs (lncRNAs) evaluated in preclinical models but unexplored in biopsy-proven kidney disease in T2DM. We aimed to determine whether there is differential expression of lncRNAs in DKD (compared with NDKD). RESEARCH DESIGN AND
methodslncRNAs preselected through database search for evaluation in humans.Discovery cohort: Preselected lncRNAs () evaluated in three components of urine (urinary cell, urinary exosome, and cell-free urine) from biopsy-proven DKD, NDKD, T2DM without kidney disease and healthy subjects (n=40/group). lncRNAs found consistently significant in all components were checked in kidney tissue. Receiver operating characteristic curves were performed to evaluate diagnostic performance.Validation cohort: Best performing lncRNA (in discovery cohort) evaluated in independent cohort. CLINICAL UTILITY: The utility of identified lncRNAs was further assessed for clinical decision-making.
resultsDiscovery cohort: Level of MALAT1 and PVT1 differed in all urinary components of DKD and elevated in kidney biopsy tissue. MALAT1 showed the most consistent results. Urinary cell-derived MALAT1 showed the most consistent results (ΔCt <8.3, sensitivity 90%, specificity 89.6% OR 53.9, p<0.0001) to differentiate DKD from NDKDValidation cohort: Urinary cell-derived MALAT1 showed sensitivity (90%) and specificity (88.5%). CLINICAL UTILITY: Addition of MALAT1 to currently existing clinical/biochemical discriminators of DKD from NDKD helps improve clinical decision making, with a net reclassification improvement (NRI) of 0.53, 64% of DKD cases were correctly reclassified to a higher probability of disease (NRI+ = 0.280), and 62.5% of NDKD controls were correctly reclassified to a lower probability of disease (NRI- = 0.250).
conclusionsUrinary cell-derived MALAT1 improves the ability to differentiate DKD from NDKD over and above currently used clinical and biochemical parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.